Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
The King of Weight Loss Peptides
If you've heard of Ozempic, you've heard of semaglutide. Originally for Type 2 diabetes, it became a phenomenon when people started losing 15-20% of their body weight.
How It Works
Simple Explanation
Mimics GLP-1, a hormone that tells your brain you're full, slows digestion, and regulates blood sugar.
Technical Details
GLP-1 receptor agonist binding to hypothalamus, pancreas, and gut receptors. 94% homology to native GLP-1 provides ~7 day half-life.
Pharmacokinetics & Storage
Half-Life
~7 days
Duration in circulation
Storage Requirements
Protect from light. Do not freeze. Discard pen 56 days after first use even if medication remains.
Research Timeline: What Studies Have Observed
Based on clinical trial data and published research. Individual responses may vary significantly.
Weeks 1-4
Studies observed initial appetite reduction. Some participants reported mild GI effects as the body adjusts. Weight loss typically begins.
Weeks 5-8
Research indicates appetite suppression becomes more pronounced. Clinical data shows average 3-5% body weight reduction by this point.
Weeks 9-16
According to STEP trials, significant weight loss momentum observed. Many participants reported reduced 'food noise' and improved satiety signals.
Weeks 17-24
Studies demonstrate continued weight loss trajectory. Metabolic markers often show improvement in blood glucose and lipid panels.
Weeks 24+
Clinical trials observed weight loss plateau around 68 weeks with maintenance of ~15-20% body weight reduction in responders.
Benefits
- 15-20% body weight loss in clinical trials
- Reduced appetite and 'food noise'
- Improved blood sugar control
- Cardiovascular benefits
- Reduced inflammation markers
Potential Side Effects
Nausea
Very common (40-50%)
Improves with slow titration
Vomiting
Common (25%)
Diarrhea
Common (20%)
Constipation
Common (15%)
Pancreatitis
Rare
Seek care if severe abdominal pain
Known Interactions
Based on clinical research and pharmacological studies. Always consult a healthcare provider about potential interactions.
Insulin & Sulfonylureas
cautionResearch indicates increased hypoglycemia risk when combined. Clinical protocols often reduce insulin dosing.
Oral Medications
monitorStudies suggest delayed gastric emptying may affect absorption timing of oral drugs.
Alcohol
cautionClinical observations note increased nausea and potential hypoglycemia risk. Research protocols recommend moderation.
Warfarin
monitorCase reports suggest potential INR changes. Research protocols recommend monitoring.
Research Highlights
FLOW Trial (Kidney Outcomes) (2024)
24% reduction in kidney disease progression in patients with type 2 diabetes and CKD
View StudySTEP-HFpEF Trial (2024)
Significant improvement in heart failure symptoms and exercise capacity in HFpEF patients
View StudyCagriSema Combination (2024)
Semaglutide + Cagrilintide combination achieved up to 22.7% weight loss in Phase 2
View StudyFrequently Asked Questions
How long until research studies observed weight loss?
What happens if a dose is missed in research protocols?
Why do studies recommend slow dose titration?
Can weight return after discontinuation?
What about 'Ozempic face'?
Who Is It For
- BMI ≥30 (obesity)
- BMI ≥27 with weight-related conditions
- Type 2 diabetics
- Those who've failed diet/exercise
Who Should Avoid
- Family history of medullary thyroid cancer
- History of pancreatitis
- Pregnant/planning pregnancy
How It Compares
Research-based comparisons with similar peptides. Individual responses and circumstances should guide decisions.
Studies show tirzepatide (dual GLP-1/GIP agonist) produced greater average weight loss (~22% vs ~15%) in head-to-head comparisons, though individual responses vary.
Early phase trials suggest retatrutide (triple agonist) may produce the highest weight loss yet (~24%), but it remains in clinical development.
Research Dosing Protocols
Common Research Protocol
Start 0.25mg weekly, titrate to 2.4mg over 16-20 weeks
Administration Frequency (per studies)
Once weekly (injection) or daily (oral)
Delivery Methods
Available Forms
- • Subcutaneous injection (Ozempic, Wegovy)
- • Oral tablet (Rybelsus)
⚠️ Not Medical Advice: Dosing information is compiled from published research and clinical studies for educational purposes only. This is not a recommendation. All peptide research should be conducted by qualified professionals in controlled research environments. Consult a healthcare provider before considering any protocol.
Cost Context
Brand-name Ozempic/Wegovy typically ranges $900-1,500/month without insurance. Compounded versions, where legally available, may range $150-400/month. Insurance coverage varies significantly.
Prices vary by region, source, and insurance coverage. This is general context only.
⚠️ Important Disclaimer
This information is for educational purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use by the FDA. Always consult with a qualified healthcare provider before starting any peptide protocol. PepGains does not sell peptides and is not responsible for how this information is used. All timeline and efficacy information is based on published research and clinical trials - individual results may vary significantly.